Country: United States
Sector: Health Care
Website: http://www.abbvie.comAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
3.45% (5y avg: 3.96%)
6.38 USD
July 15, 2025
266.46%
Year | Total Dividends |
---|---|
2026 | 3.56 USD |
May 15, 2026 (estimated) | 1.7789 |
Feb. 15, 2026 (estimated) | 1.7789 |
2025 | 6.60 USD |
Nov. 15, 2025 (estimated) | 1.6813 |
Aug. 15, 2025 | 1.6400 |
May 15, 2025 | 1.6400 |
Feb. 14, 2025 | 1.6400 |
2024 | 6.20 USD |
Nov. 15, 2024 | 1.5500 |
Aug. 15, 2024 | 1.5500 |
May 15, 2024 | 1.5500 |
Feb. 15, 2024 | 1.5500 |
2023 | 5.92 USD |
Nov. 15, 2023 | 1.4800 |
Aug. 15, 2023 | 1.4800 |
May 15, 2023 | 1.4800 |
Feb. 15, 2023 | 1.4800 |
2022 | 5.64 USD |
Nov. 15, 2022 | 1.4100 |
Aug. 15, 2022 | 1.4100 |
May 16, 2022 | 1.4100 |
Feb. 15, 2022 | 1.4100 |
2021 | 5.20 USD |
Nov. 15, 2021 | 1.3000 |
Aug. 16, 2021 | 1.3000 |
May 14, 2021 | 1.3000 |
Feb. 16, 2021 | 1.3000 |
2020 | 4.72 USD |
Nov. 16, 2020 | 1.1800 |
Aug. 14, 2020 | 1.1800 |
May 15, 2020 | 1.1800 |
Feb. 14, 2020 | 1.1800 |
2019 | 4.28 USD |
Nov. 15, 2019 | 1.0700 |
Aug. 15, 2019 | 1.0700 |
May 15, 2019 | 1.0700 |
Feb. 15, 2019 | 1.0700 |
2018 | 3.59 USD |
Nov. 15, 2018 | 0.9600 |
Aug. 15, 2018 | 0.9600 |
May 15, 2018 | 0.9600 |
Feb. 15, 2018 | 0.7100 |
2017 | 2.56 USD |
Nov. 15, 2017 | 0.6400 |
Aug. 15, 2017 | 0.6400 |
May 15, 2017 | 0.6400 |
Feb. 15, 2017 | 0.6400 |
2016 | 2.28 USD |
Nov. 15, 2016 | 0.5700 |
Aug. 15, 2016 | 0.5700 |
May 16, 2016 | 0.5700 |
Feb. 16, 2016 | 0.5700 |
2015 | 2.02 USD |
Nov. 16, 2015 | 0.5100 |
Aug. 14, 2015 | 0.5100 |
May 15, 2015 | 0.5100 |
Feb. 13, 2015 | 0.4900 |
2014 | 1.66 USD |
Nov. 17, 2014 | 0.4200 |
Aug. 15, 2014 | 0.4200 |
May 15, 2014 | 0.4200 |
Feb. 14, 2014 | 0.4000 |
2013 | 1.60 USD |
Nov. 15, 2013 | 0.4000 |
Aug. 15, 2013 | 0.4000 |
May 15, 2013 | 0.4000 |
Feb. 15, 2013 | 0.4000 |
Yearly aggregated dividends
AbbVie Inc.
Aug 15, 2025 Upcoming
Dividend
1.64 USD |
AbbVie Inc.
May 15, 2025 Paid
Dividend
1.64 USD |
AbbVie Inc.
Feb 14, 2025 Paid
Dividend
1.64 USD |
AbbVie Inc.
Nov 15, 2024 Paid
Dividend
1.55 USD |
AbbVie Inc.
Aug 15, 2024 Paid
Dividend
1.55 USD |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion